Genomics in leukaemia in clinical practice: past, present and the future

Abstract

Acute myeloid leukaemia (AML) is a heterogeneous group of diseases with diverse genetic drivers. The conventional one-size-fits-all approach with chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT) has reached an impasse, and only about 40% of patients can achieve long-term survival. Disease heterogeneities have also hampered the development of effective therapy applicable to the multitude of AML subtypes. Recent advances in cancer genetics and genomics have shed light on the genetic underpinnings of AML and both inter-individual and intra-tumoral heterogeneities. These new pieces of knowledge have begun to impact the management and prognostication of AML. They also provide the foundation for personalized treatment for this group of diseases.

Keywords

Acute myeloid leukaemia / next-generation sequencing / measurable residual disease / personalized medicine

References

[1] Priestley P,Lolkema MP.Pan-cancer whole-genome analyses of metastatic solid tumours.Nature2019;575:210-6 PMCID:PMC6872491

[2] Rowley JD.Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.Nature1973;243:290-3

[3] Rowley JD,Dougherty C.15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia.Lancet1977;1:549-50

[4] Döhner H,Löwenberg B.Towards precision medicine for AML.Nat Rev Clin Oncol2021;18:577-90

[5] Schlenk RF,Krauter J.Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.N Engl J Med2008;358:1909-18

[6] Cher CY,Au CH.Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.Blood Cancer J2016;6:e442 PMCID:PMC5030377

[7] Leung GMK,Ng NKL.Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations.Am J Hematol2019;94:650-7

[8] Stone RM,Sanford BL.Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation.N Engl J Med2017;377:454-64 PMCID:PMC5754190

[9] Hills RK,Appelbaum FR.Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.Lancet Oncol2014;15:986-96 PMCID:PMC4137593

[10] DiNardo CD,Pullarkat V.Azacitidine and venetoclax in previously untreated acute myeloid leukemia.N Engl J Med2020;383:617-29

[11] Sakurai M,Kakati S.Letter: 8-21 translocation and missing sex chromosomes in acute leukaemia.Lancet1974;2:227-8

[12] Döhner H,Appelbaum FR.Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.Blood2022;140:1345-77

[13] Ley TJ,Ding L.DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome.Nature2008;456:66-72

[14] Mardis ER,Dooling DJ.Recurring mutations found by sequencing an acute myeloid leukemia genome.N Engl J Med2009;361:1058-66

[15] Marcucci G,Wu YZ.IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.J Clin Oncol2010;28:2348-55 PMCID:PMC2881719

[16] DiNardo CD,de Botton S.Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML.N Engl J Med2018;378:2386-98

[17] Stein EM,Pollyea DA.Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.Blood2017;130:722-31

[18] Tsui SP,Saw NY.Redefining prognostication of de novo cytogenetically normal acute myeloid leukemia in young adults.Blood Cancer J2020;10:104 PMCID:PMC7573626

[19] Khoury JD,Abla O.The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms.Leukemia2022;36:1703-19 PMCID:PMC9252913

[20] Krigstein M,Wei AH.Applying molecular measurable residual disease testing in acute myeloid leukaemia.Pathology2023;55:1-7

[21] Heuser M,Ossenkoppele GJ.2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD working party.Blood2021;138:2753-67 PMCID:PMC8718623

[22] Burd A,Ruppert AS.Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.Nat Med2020;26:1852-8 PMCID:PMC8530434

[23] Lam SS,He BL.Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia.Sci Transl Med2016;8:359ra129

[24] Malani D,Brück O.Implementing a functional precision medicine tumor board for acute myeloid leukemia.Cancer Discov2022;12:388-401 PMCID:PMC9762335

[25] Wang H,Cheng CK.Pharmacogenomic profiling of pediatric acute myeloid leukemia to identify therapeutic vulnerabilities and inform functional precision medicine.Blood Cancer Discov2022;3:516-35

[26] Lilljebjörn H,Mitelman F,Fioretos T.Transcriptomics paving the way for improved diagnostics and precision medicine of acute leukemia.Semin Cancer Biol2022;84:40-9